← brief for 2026-08-29 · Slowing decline

Efficacy and safety of SP16 in preventing acute kidney injury in at-risk subjects with chronic kidney disease undergoing elective cardiac surgery using the heart-lung-machine (EASE-AKI): study protocol for a prospective, randomised, double-blind, placebo-controlled clinical trial.

Article No results yet Peer reviewed

Key takeaways

A new trial is starting to test a drug called SP16 in people with kidney disease who are having planned heart surgery. Heart surgery on a heart-lung machine often injures the kidneys, and no approved drug prevents that. Patients will get either SP16 or a dummy drug, and neither they nor their doctors will know which. This is the study plan only, so there are no results yet.

Who did this work

Jobst-Schwan T · Bihlmaier K · Austin D · Gelber C · Kaemmerer-Suleiman AS · Suleiman M · Cesnjevar R · Harig F · Schiffer M

Source

Article · PubMed, CKD progression and prevention · 2026 Aug 28
https://pubmed.ncbi.nlm.nih.gov/42665834/